8月26日，深圳经济特区迎来建立45周年。 在深圳这片敢闯敢试、敢为人先的热土上，生物医药产业正以前所未有的速度崛起。从昔日以"三来一补"（即来料加工、来样加工、来件装配和补偿贸易） 为起点，到如今成为创新药与高端医疗器械的策源地，深圳生物医药产业正加速向规模超千亿元的创新高地迈进。 深圳坪山生物医药产业加速器园区 图片来源：视觉中国-VCG211420918549 从"零起步"到国际一流产业集聚高地 在深圳经济特区45年的发展历程中，产业转型升级的轨迹清晰可见，而生物医药产业亦是其中的亮丽篇章。 45年前，深圳没有一家现代化药厂，仅有几家作坊式制药车间，原料药依赖进口。45年后，深圳医药产业规模持续壮大，汇聚了众多生物医药相关的上市公 司，在创新药、高端医疗器械、生物技术等领域不断突破。 药智数据统计显示，截至2024年，深圳市累计拥有生物医药企业2780家，规上医药制造业工业总产值（2022年）499.22亿元。其中，医疗器械企业2468家， 保健品企业133家，生产化药的企业114家。 如今，深圳不再仅仅是"世界工厂"，更是"创新工场"。 从原创成果到产业龙头，这里既诞生了多个自主研发的创新治疗产品，还 ...

非药行业研究框架培训 20250815 摘要 DRG 支付方式对医疗器械使用有何影响？ DRG 支付方式会影响到医院使用的一些产品，因为它采用总包打包付费模式。 这意味着某些产品，如普通 X 射线设备、超声设备等，其使用年限一般为 3 到 4 年，而大型设备如核磁共振和 CT 则通常超过 10 年。过去几年，由于医疗新 基建扩建医院需要大量采购设备，2021 至 2022 年达到高峰，但随后在 2023 至 2024 年出现下滑。预计今年（2025 年）下半年将开始看到报表业绩体现。 体外诊断市场有哪些特点？ 医疗器械国产化率提升显著，尤其在 2018-2020 年，但电生理设备等 领域仍有提升空间。集采政策虽未影响出厂价，但压缩中间商利润，导 致终端价格下降，行业经历量价双杀后，目前接近尾声。 DRG 支付方式影响医院对普通 X 射线、超声设备（3-4 年）及大型设备 如核磁共振、CT（超 10 年）的使用年限。2021-2022 年医疗新基建 高峰后，2023-2024 年采购下滑，预计 2025 年下半年报表业绩将有所 体现。 体外诊断市场设备和试剂并重，集采主要针对试剂。生化分子基本实现 国产替代，但 ...

Core Insights - Goldman Sachs indicates a decline in hospital equipment bidding amounts in July, down 11% month-on-month, marking the third consecutive month of decline, although year-on-year growth remains at 23% [1] - The company expects that the equipment update stimulus policy in 2025 will yield results, albeit less significant than in 2024 [1] - A notable trend is the domestic substitution, with four out of nine tracked Chinese companies showing year-on-year growth, while five foreign companies experienced declines [3] Group 1: Market Trends - The ongoing regional centralized procurement is a major concern, with significant price drops observed in ultrasound equipment and CT scanners due to procurement impacts [7] - By the end of July, 30% of China's provincial regions completed centralized procurement for ultrasound equipment, leading to an average price drop of 50%-60% [10] - The average price of ultrasound equipment is expected to remain under pressure due to continued centralized procurement activities in various provinces [7][10] Group 2: Company Performance - For United Imaging Healthcare, management expresses optimism about the scale and progress of the 2025 equipment update policy, expecting smoother processes compared to 2024 [11] - United Imaging's revenue recognition cycle is longer due to delays between hospital bidding and actual installation, with expected year-on-year revenue growth of +10%/+45%/+26.8% in Q2/Q3/Q4 of 2025 [11] - For Mindray Medical, there is a slowdown in year-on-year growth for monitoring devices and ultrasound equipment, with July figures showing 21% and 24% growth respectively [14] Group 3: Investment Outlook - Mindray Medical is positioned as a leading medical device manufacturer in China, with strong domestic market momentum and potential for overseas revenue growth [20] - Goldman Sachs rates Mindray Medical as a buy, citing recovery in procurement activities and advancements in medical equipment update policies as key growth drivers [20] - United Imaging Healthcare is also rated as a buy, with expectations of rising service-related revenue and improved gross margins as market share increases [21]

Core Insights - Shantou is advancing its economic development by focusing on industrialization and modernization, particularly in the context of the 40th anniversary of its economic zone establishment [7][22] - The city is implementing a "three new, two special, one big" industrial development strategy, which includes new energy, new materials, and new generation electronic information industries [8][10] New Energy Sector - Shantou is developing a significant offshore wind power project, with an investment of 40.77 billion yuan, expected to generate an annual output value of 142 billion yuan upon reaching full production [9] - The offshore wind power industry aims to achieve an economic scale exceeding 200 billion yuan by 2030, positioning Shantou as a national hub for offshore wind power technology [9][10] New Materials Industry - The new materials sector is projected to have 302 enterprises by 2024, with an output value of 48.825 billion yuan, accounting for 17.4% of the city's industrial output [10] - Shantou is focusing on high-end, green, and clustered development in the new materials industry, aiming to create a billion-level industry cluster [10] New Generation Electronic Information Industry - Shantou is uniquely positioned as a national communication hub with six international submarine cables connecting to over 297 cities globally, accounting for over 50% of the national export bandwidth [10] - The city is leveraging its advantages to develop cross-border data services and attract investment in green computing [10] Traditional Industries Transformation - The textile and toy industries, which contribute significantly to national production, are undergoing transformation to address challenges such as small enterprise size and low product quality [12][15] - Shantou is promoting high-end, intelligent, and green upgrades in these traditional sectors, with significant investments in smart manufacturing and digital transformation [12][14] Health Industry Development - The health industry in Shantou is expanding, with a focus on pharmaceuticals, medical devices, and health services, supported by local enterprises and research institutions [16][18] - The health industry has surpassed 30 billion yuan in scale, with ongoing projects totaling approximately 138 billion yuan [19] Business Environment Improvement - Shantou is enhancing its business environment to attract investment, with initiatives such as streamlined administrative processes and improved regulatory frameworks [20][21] - The city aims to create a market-oriented, law-based, and international business environment to support high-quality economic development [21][22]

Group 1 - Wuxi has seen a significant increase in foreign investment, with 168 new foreign projects and actual foreign investment of $2.21 billion in the first half of the year, ranking second in the province and accounting for 19.1% of the total [1] - Major projects such as AstraZeneca's new small molecule drug factory, with a total investment of $475 million, highlight the city's appeal to foreign investors, with AstraZeneca having invested over $1 billion in Wuxi since 1993 [2] - Wuxi's industrial strength and open cooperation environment have attracted over 7,200 foreign enterprises, with one-quarter of the world's top 500 companies investing in the city [3] Group 2 - The actual foreign investment in Wuxi's manufacturing sector reached $860 million, while the modern service sector accounted for $1.34 billion, representing 60.9% of the total foreign investment in the city [3] - Wuxi has introduced policies to encourage foreign companies to reinvest, including a series of measures to support domestic reinvestment, which has led to 13 foreign companies reinvesting a total of $890 million, accounting for 40.2% of the city's actual foreign investment [5] - The city is diversifying its foreign investment sources, with investments from regions like Hong Kong dropping below 50% for the first time, while investments from Japan, South Korea, and Europe have increased significantly [6] Group 3 - Wuxi has become a pilot city for QFLP, facilitating foreign capital investment in domestic industries, with the average approval time for QFLP fund establishment reduced to just two weeks [7] - The financial sector in Wuxi attracted $800 million in actual foreign investment in the first half of the year, accounting for 36.3% of the total, with a year-on-year increase of 11.1% [7] - The city has implemented measures to create a more convenient business environment for foreign nationals, enhancing the overall investment climate [8]

Group 1: Company Developments - United Imaging announced a plan to reduce holdings by up to 13,376,600 shares, corresponding to a market value of approximately 1.78 billion yuan, marking the second large-scale reduction following a cash-out of 894 million yuan in July 2024 [1][2] - The share reduction involves five employee stockholding platforms, with the shares being original stocks granted before the company's IPO, which became tradable on August 22, 2023 [2] - Despite a decline in revenue and net profit for 2024, United Imaging maintains its position as a leader in the domestic medical imaging sector, with a market share of 35% for PET-CT and over 20% for MRI equipment [3][4] Group 2: Financial Performance - United Imaging's revenue for 2024 was 10.3 billion yuan, a year-on-year decrease of 9.73%, while net profit dropped by 36.08% to 1.262 billion yuan [3] - The decline in performance is attributed to the impact of domestic equipment update policies and the lengthy market introduction period for new high-end products [3] Group 3: Competitive Landscape - In contrast to United Imaging's challenges, Mindray Medical is accelerating its global expansion, with the opening of a new base in Wuhan, representing a significant investment of 4.5 billion yuan [5][6] - Mindray has established a robust domestic network with 36 subsidiaries and over 30 branches, while also expanding its international presence with 63 overseas subsidiaries in about 40 countries [6][8] - The company is focusing on localized operations, with over 90% of its overseas team being local hires, and is customizing products to meet regional market needs [8] Group 4: Strategic Initiatives - Mindray's global strategy includes significant R&D investments, with 4.008 billion yuan allocated in 2025, accounting for 10.91% of its revenue [7] - The Wuhan base will focus on minimally invasive surgery and orthopedic fields, enhancing Mindray's production capabilities [6][7] - There are ongoing discussions about a potential second listing in Hong Kong, which could raise at least 1 billion USD to support global expansion efforts [8]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [7] Core Insights - The continuous deepening of equipment update policies and fiscal support is driving the recovery of the medical equipment procurement market [4][12] - In the first half of 2025, the number of disclosed budget projects for medical equipment updates reached 212, with a total budget amount of 15.34 billion yuan [14] - The procurement scale and amount of medical devices are growing across regions, with a notable increase in the central and western regions [5][26] Summary by Sections 1. Equipment Update Policies and Market Recovery - The release of the equipment update policy in March 2024 and subsequent implementation plans by various government departments have accelerated the procurement process [4][12] - In the first half of 2025, the number of project approvals and procurement intentions reached 212 and 334, with total amounts of 15.34 billion yuan and 14.23 billion yuan respectively [14][18] 2. Regional Distribution and Procurement Trends - The procurement of large medical imaging equipment remains a focus, with a trend of "volume in the west, value in the east" observed [5][19] - The central and western regions are seeing significant growth in procurement, with the central region's procurement scale exceeding 53% [26][28] 3. County Medical Community and Hospital Equipment Updates - The county medical community's bidding process is accelerating, with a significant portion of procurement occurring in tertiary hospitals, which account for 61.11% of the procurement scale [35][32] - In the first half of 2025, the procurement scale for county medical communities reached 4.3 billion yuan, while urban hospitals accounted for 4.5 billion yuan [34][33] 4. Market Performance and Subsector Trends - In the first week of August 2025, the pharmaceutical and biotechnology sector rose by 2.95%, outperforming the CSI 300 index by 4.7 percentage points [38] - The chemical preparation sector showed the largest increase at 5.48%, while the medical equipment sector experienced the largest decline at 1.43% [42][43]

Summary of Conference Call on Medical Device Industry Industry Overview - The medical device industry is transitioning its valuation system from DCF to PB or dividend valuation due to the impact of centralized procurement policies. However, by 2025, the policy direction is expected to become more rational, with price increases observed in certain segments like coronary stents, indicating a healthier industry overall [1][3][2]. Key Companies and Their Performance 1. **Shanwaishan** - Expected profit for 2025 is between 160-180 million yuan, with revenue exceeding 800 million yuan. The equipment segment is projected to grow at 15%-20%, while the consumables segment may exceed 40%. The compound annual growth rate (CAGR) over the next three to five years is anticipated to reach 25%-30% [1][7]. - The self-produced consumables ratio has increased to over 50%, positively impacting overall gross and net profit margins [1][8]. 2. **Aidi Te** - Aidi Te's zirconia materials are not affected by centralized procurement, with overseas business growth outpacing domestic growth. Sales from 3D printer products are expected to exceed 100 million yuan, contributing at least 20 million yuan in profit. The industry growth rate is projected to be over 10% due to aging demographics [1][10]. 3. **Times Angel** - Times Angel anticipates over 50% growth in overseas business for 2025, with domestic and international sales volumes becoming comparable. The company aims for profitability in overseas operations by 2026, with a target market capitalization of 15 billion yuan based on domestic profit and sales scale [1][11]. Market Trends and Changes - The medical device industry is experiencing positive changes in 2025, with a controlled reduction in prices due to centralized procurement policies. Some segments, such as high-value consumables, are seeing price increases, particularly in ophthalmic artificial crystals and OK lenses [3][13]. - The implementation of anti-involution policies is expected to benefit mid-to-low-end consumables, allowing large manufacturers to leverage automated production lines to reduce costs [3][27]. Investment Recommendations - Recommended companies include Shanwaishan, Aidi Te, and Times Angel, with Shanwaishan showing strong performance in bidding data and overseas business growth, particularly in blood dialysis equipment [1][5]. - The high-value consumables sector, especially in ophthalmology and cardiology, is highlighted as a key area for investment, with specific companies like Aidi, Opcon Vision, and Haohai Medical recommended for their strong market positions [1][13]. Future Outlook - The overall valuation levels in the medical device sector are low, with potential for improvement in both performance and valuation levels, indicating a "Davis Double Play" scenario [1][6]. - The industry is expected to continue its growth trajectory, with a focus on brand volume and the gradual reduction of price differences among similar products, facilitating domestic replacements for foreign products [1][27].

Group 1 - The core viewpoint is that the procurement scale of medical equipment in China is expected to see significant growth in the first half of 2025 due to the implementation of national and local government policies for equipment updates [1] - In June 2025, the domestic medical equipment procurement scale is projected to increase by 25% year-on-year, with a cumulative growth of 41% in the first half of the year [1] - High-end equipment categories such as CT, MR, and DR are experiencing particularly notable procurement growth, with June figures showing CT up by 20%, MR by 32%, and DR by 47% year-on-year [1] Group 2 - The implementation of equipment update policies is expected to be a long-term driving force for medical equipment procurement [1] - A target has been set for medical and health equipment investment to grow by over 25% by 2027 compared to 2023, as outlined in a notice from four ministries [1] - Although large-scale procurement plans have been announced for 2024, the actual tendering rate remains low, with many projects expected to be realized in 2025, contributing to significant market growth [1]

Investment Rating - The report initiates coverage with a "Strong Buy" rating for the company [4][5]. Core Viewpoints - The company is a leading domestic player in ultrasound and endoscopy, with a comprehensive product matrix and strong technological accumulation, driving rapid growth through R&D breakthroughs and import substitution [1][13]. - The company is well-positioned to benefit from the recovery of terminal procurement, which is expected to release performance elasticity in the short term [1][25]. Summary by Sections 1. Dual-Engine Growth of Ultrasound and Endoscopy - The company has established a strong competitive advantage in the medical device market, with a product line covering ultrasound imaging, endoscopy, minimally invasive surgery, and cardiovascular intervention [13]. - The ultrasound business is expected to generate revenue of 1.183 billion yuan in 2024, while the endoscopy business is projected to reach 795 million yuan, with a five-year CAGR of 22.18% [2][29]. 2. Product Line Highlights - The company is a pioneer in developing core technologies for color Doppler ultrasound equipment, with plans to launch an AI detection technology for obstetric ultrasound in 2025 [2][15]. - The endoscopy market is experiencing rapid growth, with the company enhancing its product offerings and achieving clinical recognition [3][16]. 3. Financial Performance and Forecast - The company’s revenue is projected to reach 2.412 billion yuan in 2025, with a year-on-year growth rate of 20%, and net profit is expected to be 359 million yuan, reflecting a significant increase of 152% [4][9]. - The company has maintained a stable revenue growth trajectory, with a CAGR of 11.58% from 2018 to 2023 [25]. 4. Management and Ownership Structure - The company has a concentrated ownership structure, with the founders holding a combined 44.24% of shares, ensuring stability in management [19][23]. - The management team possesses extensive experience in the medical device industry, contributing to the company's strategic direction [23][24]. 5. Market Position and Competitive Landscape - The company ranks second among domestic manufacturers in the ultrasound market and third in the domestic endoscopy market, with significant growth potential in high-end segments [29][46]. - The report highlights the ongoing shift towards domestic high-end product replacement, indicating a favorable competitive landscape for the company [46].